BioSpace News Archive

Expectations are increasing as a Korean bio-tech company has succeeded in solving the problem of low absorption which has been one of the biggest obstacles for the repositioning of Niclosamide, an anthelmintic, as the first orally ingested treatment for COVID-19.

- Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on October 29, 2020 , and the Company’s ordinary shares will begin trading on a split-adjusted basis on the Nasdaq C

Thermo Fisher and Symphogen continue work to support the development of innovative cancer treatments through optimization of protein characterization and quality monitoring mass spectrometry workflows

LabCentral, the first-of-its-kind shared laboratory space designed as a launchpad for high-potential biotech startups, today announced it has partnered with BioLabs and E25Bio to launch the Cambridge Consortium for Rapid COVID-19 Tests (CCRCT)

- PDL BioPharma, Inc. (“PDL” or “the Company”) (Nasdaq: PDLI) announces that it will release its third quarter 2020 financial results for the period ended September 30, 2020 , on Monday, November 9, 2020 after market close. PDL’s management will host a conference call and webcast that day at 4:30 p.m. Eastern time to dis

IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the Company will participate in the following, upcoming, virtual investor conferences in November: 29 th Annual Credit Suisse Virtual Healthcare Conference Glenn P. Sblendorio, Chief Executive Officer and President and Pravin U. Dugel, M.D., Executive Vice President and Chief Strategy and Business Officer will participate in a fireside chat on Tuesday, November

IMT-002 is the first oral genetically targeted drug candidate to be tested in type 1 diabetes patients Completed Phase 1a study showed no adverse events in all patient groups Therapeutic approach blocks activity of specific genes known to play a strong role in autoimmune disease development

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2020 financial results on Thursday, November 5, 2020. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET. T

Astrotech Corporation (NASDAQ: ASTC), today announced that it has entered into definitive agreements with several institutional investors for the purchase and sale of 2,887,906 shares of Astrotech’s common stock, at a purchase price of $2.15 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about October 30, 2020, subject to the satisf

Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,403,509 shares of its common stock at a price to the public of $28.50 per share. In addition, Forte has granted to the underwriters a 30-day option to purchase up to an additional 210,526 shares of common stock at the public offering price of $28.50 per share, less under